Skip to main content
Journal cover image

Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE.

Publication ,  Journal Article
Goto, S; Merrill, P; Wallentin, L; Wojdyla, DM; Hanna, M; Avezum, A; Easton, JD; Harjola, V-P; Huber, K; Lewis, BS; Parkhomenko, A; Zhu, J ...
Published in: Eur Heart J Cardiovasc Pharmacother
April 1, 2018

AIMS: We investigated baseline characteristics, antithrombotic use, and clinical outcomes of patients with atrial fibrillation (AF) and a thrombo-embolic event in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study to better inform the care of these high-risk patients. METHOD AND RESULTS: Thrombo-embolic events were defined as stroke (ischaemic or unknown cause) or systemic embolism (SE). Clinical outcomes were estimated using the Kaplan-Meier method. All-cause mortality and International Society on Thrombosis and Haemostasis (ISTH) major bleeding after events were analysed using a Cox proportional hazards model with time-dependent covariates. Of 18 201 patients in ARISTOTLE, 365 experienced a thrombo-embolic event [337 strokes (ischaemic or unknown cause), 28 SE]; 46 (12.6%) of which were fatal. In the 30 days before and after a thrombo-embolic event, 11% and 37% of patients, respectively, were not taking an oral anticoagulant. During follow-up (median 1.8 years), 22 patients (7.1%/year) had a recurrent stroke, 97 (30.1%/year) died, and 10 (6.7%/year) had major bleeding. Compared with patients without a thrombo-embolic event, the short- and long-term adjusted hazards of death in patients with a thrombo-embolic event were high [≤30 days: hazard ratio (HR) 54.3%, 95% confidence interval (95% CI) 41.4-71.3; >30 days: HR 3.5, 95% CI 2.5-4.8; both P < 0.001]. The adjusted hazards of major bleeding were also high short-term (HR 10.37, 95% CI 3.87-27.78; P < 0.001) but not long-term (HR 1.7, 95% CI: 0.77-3.88; P = 0.18). CONCLUSIONS: Thrombo-embolic events were rare but associated with high short- and long-term morbidity and mortality. Substantial numbers of patients are not receiving oral anticoagulattherapy before and, despite this risk, after a first thrombo-embolic event. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT00412984).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Heart J Cardiovasc Pharmacother

DOI

EISSN

2055-6845

Publication Date

April 1, 2018

Volume

4

Issue

2

Start / End Page

75 / 81

Location

England

Related Subject Headings

  • Treatment Outcome
  • Thromboembolism
  • Survival Rate
  • Risk Assessment
  • Retrospective Studies
  • Middle Aged
  • Male
  • Incidence
  • Humans
  • Global Health
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goto, S., Merrill, P., Wallentin, L., Wojdyla, D. M., Hanna, M., Avezum, A., … Alexander, J. H. (2018). Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother, 4(2), 75–81. https://doi.org/10.1093/ehjcvp/pvy002
Goto, Shinya, Peter Merrill, Lars Wallentin, Daniel M. Wojdyla, Michael Hanna, Alvaro Avezum, J Donald Easton, et al. “Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE.Eur Heart J Cardiovasc Pharmacother 4, no. 2 (April 1, 2018): 75–81. https://doi.org/10.1093/ehjcvp/pvy002.
Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, et al. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):75–81.
Goto, Shinya, et al. “Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE.Eur Heart J Cardiovasc Pharmacother, vol. 4, no. 2, Apr. 2018, pp. 75–81. Pubmed, doi:10.1093/ehjcvp/pvy002.
Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, Easton JD, Harjola V-P, Huber K, Lewis BS, Parkhomenko A, Zhu J, Granger CB, Lopes RD, Alexander JH. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):75–81.
Journal cover image

Published In

Eur Heart J Cardiovasc Pharmacother

DOI

EISSN

2055-6845

Publication Date

April 1, 2018

Volume

4

Issue

2

Start / End Page

75 / 81

Location

England

Related Subject Headings

  • Treatment Outcome
  • Thromboembolism
  • Survival Rate
  • Risk Assessment
  • Retrospective Studies
  • Middle Aged
  • Male
  • Incidence
  • Humans
  • Global Health